5/13/2013 | PP | Dyax arranges $30 million registered direct sale of preferreds, stock
|
1/4/2012 | BKPV | Dyax gets $20 million loan plus commitment for additional $60 million
|
12/23/2010 | CVHYPF | Dyax files $100 million shelf for stock, debt and preferreds
|
6/21/2010 | PP | New Issue: Dyax announces plans for $2.5 million placement of common stock
|
12/31/2008 | PP | Outlook 2009: Market shrinks in 2008, outlook hazy; private equity, preferreds could play bigger role
|
12/31/2008 | CVHY | Dyax files $100 million shelf registration
|
10/30/2008 | PP | New Issue: Dyax arranges $50 million equity financing facility with Azimuth
|
10/30/2008 | PP | Market Commentary: Dyax secures $50 million facility; Advanced Cell investor doubles deal; Rubicon, Radiant to sell stock
|
8/6/2008 | PP | New Issue: Dyax concludes $50 million loan with Cowen Healthcare Royalty Partners
|
8/6/2008 | PP | Market Commentary: Dyax completes $50 million deal; Achillion hopes for $42 million; Marchpole concludes £2.5 million
|
2/21/2007 | SS | Market Commentary: Jupitermedia, Getty gain; Loral in focus on SatMex sale; Whole Foods, Wild Oats rise; Novastar falls
|
10/25/2006 | BT | Dyax consumes $25 million of cash since start of '06; year-end total expected to be $40 million
|
10/18/2006 | BT | Dyax says FDA regulatory pathway for DX-88 is now clear; expects approval in 2008
|
9/22/2006 | BT | Market Commentary: Amgen leads sector lower; Dyax gains on Kos' loss; Oscient rises; Gene Logic up; Discovery Labs off
|
9/7/2006 | BT | Dyax, Serono enter agreement for antibody discovery
|
8/31/2006 | BT | Dyax to hold new DX-88 trial; FDA confirms 30 mg subcutaneous dose
|
8/24/2006 | BT | Dyax gets $30 million for phage display licensing, funded research program
|
7/26/2006 | BT | Dyax reports second-quarter net loss of $8.7 million
|
5/22/2006 | BT | Dyax, ICOS to discover therapeutic antibodies
|
5/22/2006 | BT | Market Commentary: Adventrx gains after pulling deal; Dyax gains, Icos slips on pact; Cell Therapeutics declines 7%
|
5/15/2006 | BT | Market Commentary: BioMimetic goes south; Sirna off on new deal; Cambridge rockets on buyout; Threshold extends fall
|
4/17/2006 | BT | Dyax files shelf for 11 million shares, warrants, units
|
4/17/2006 | BT | Market Commentary: Invitrogen falls on lower sales forecast; Alkermes rises, dips; Targacept, Vanda gain; Dyax off
|
3/9/2006 | BT | New Issue: Dyax raises $31 million in spot follow-on of 5.5 million shares at $5.65 each
|
3/9/2006 | BT | Market Commentary: NPS Pharma weak ahead of FDA; Dyax plunges; Insmed up slightly; Vertex dives; Elan off, Biogen up
|
3/8/2006 | BT | Dyax in market with spot sale of 6.5 million shares via Deutsche
|
3/8/2006 | BT | Market Commentary: Alexza IPO gets off; Cepheid off; Dyax deal seen; Elan, Biogen up; Neurocrine shakes off trial miss
|
3/6/2006 | BT | Dyax reports positive top-line results from phase 2 trial of DX-88 for hereditary angioedema
|
1/10/2006 | BT | Dyax issued fifth U.S. patent for Phage Display
|
12/20/2005 | BT | Debiopharm, Dyax revise Depelestat development agreement
|
12/8/2005 | BT | Dyax, Genzyme begin phase 3 trial of DX-88 for hereditary angioedema
|
11/7/2005 | BT | Dyax announces positive final results from phase I trial of subcutaneous DX-88
|
8/29/2005 | BT | Dyax files to sell 9 million shares, estimates proceeds at $52.8 million
|
5/20/2005 | PP | New Issue: Dyax plans direct placement of stock for $25.26 million
|
5/20/2005 | PP | Market Commentary: Amarin arranges $17.81 million direct offering; volume ends week on a strong note
|